LIFECORE BIOMEDICAL, INC. Cost of Goods Sold (Deprecated 2018-01-31)
LIFECORE BIOMEDICAL, INC. (LFCR) reported Cost of Goods Sold (Deprecated 2018-01-31) of $129.19 million for the 3-month period ending 2018-02-25, per its 10-Q filed 2018-04-05.
Discontinued › Expense Statement › Cost of Sales
us-gaap:CostOfGoodsSold · last filed 2018-04-05
- LIFECORE BIOMEDICAL, INC. cost of goods sold (deprecated 2018-01-31) for the quarter ending 2018-02-25 was $129.19M, a 14.19% increase year-over-year.
- LIFECORE BIOMEDICAL, INC. cost of goods sold (deprecated 2018-01-31) for the quarter ending 2017-11-26 was $120.70M, a 3.24% increase year-over-year.
- LIFECORE BIOMEDICAL, INC. cost of goods sold (deprecated 2018-01-31) for the quarter ending 2017-08-27 was $104.07M, a 6.45% decline year-over-year.
- LIFECORE BIOMEDICAL, INC. cost of goods sold (deprecated 2018-01-31) for the quarter ending 2017-05-28 was $107.77M, a 4.23% decline year-over-year.
- LIFECORE BIOMEDICAL, INC. cost of goods sold (deprecated 2018-01-31) for fiscal 2017 was $449.07M, a 4.48% decline from fiscal 2016.
- LIFECORE BIOMEDICAL, INC. cost of goods sold (deprecated 2018-01-31) for fiscal 2016 was $470.14M, a 0.78% decline from fiscal 2015.
- LIFECORE BIOMEDICAL, INC. cost of goods sold (deprecated 2018-01-31) for fiscal 2015 was $473.85M, a 14.39% increase from fiscal 2014.
- LIFECORE BIOMEDICAL, INC. cost of goods sold (deprecated 2018-01-31) for fiscal 2014 was $414.25M, a 9.32% increase from fiscal 2013.
| Period end | Cost of Goods Sold (Deprecated 2018-01-31) 3 month | Cost of Goods Sold (Deprecated 2018-01-31) 3 month as first filed | Cost of Goods Sold (Deprecated 2018-01-31) 6 month | Cost of Goods Sold (Deprecated 2018-01-31) 6 month as first filed | Cost of Goods Sold (Deprecated 2018-01-31) 9 month | Cost of Goods Sold (Deprecated 2018-01-31) 9 month as first filed | Cost of Goods Sold (Deprecated 2018-01-31) 12 month | Cost of Goods Sold (Deprecated 2018-01-31) 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2018-02-25 | $129.19M 10-Q · filed 2018-04-05 | $249.90M derived: sum of 2 quarters · filed 2018-04-05 | $353.97M 10-Q · filed 2018-04-05 | $461.74M derived: sum of 4 quarters · filed 2018-04-05 | ||||
| 2017-11-26 | $120.70M 10-Q · filed 2018-01-05 | $224.78M 10-Q · filed 2018-01-05 | $332.55M derived: sum of 3 quarters · filed 2018-03-15 | $445.69M derived: sum of 4 quarters · filed 2018-04-05 | ||||
| 2017-08-27 | $104.07M 10-Q · filed 2017-09-28 | $211.84M derived: sum of 2 quarters · filed 2018-03-15 | $324.98M derived: sum of 3 quarters · filed 2018-04-05 | $441.89M derived: sum of 4 quarters · filed 2018-04-05 | ||||
| 2017-05-28 | $107.77M derived: 10-K/A 12 month − 10-Q 9 month · filed 2018-03-15 | $220.91M derived: sum of 2 quarters · filed 2018-04-05 | $337.82M derived: sum of 3 quarters · filed 2018-04-05 | $449.07M 10-K/A · filed 2018-03-15 | ||||
| 2017-02-26 | $113.14M 10-Q · filed 2018-04-05 | $230.05M derived: sum of 2 quarters · filed 2018-04-05 | $341.30M 10-Q · filed 2018-04-05 | $453.83M derived: sum of 4 quarters · filed 2018-04-05 | ||||
| 2016-11-27 | $116.91M 10-Q · filed 2018-01-05 | $228.16M 10-Q · filed 2018-01-05 | $340.69M derived: sum of 3 quarters · filed 2018-03-15 | $457.75M derived: sum of 4 quarters · filed 2018-03-15 | ||||
| 2016-08-28 | $111.25M 10-Q · filed 2017-09-28 | $223.78M derived: sum of 2 quarters · filed 2018-03-15 | $340.84M derived: sum of 3 quarters · filed 2018-03-15 | $464.01M derived: sum of 4 quarters · filed 2018-03-15 | ||||
| 2016-05-29 | $112.53M derived: 10-K/A 12 month − 10-Q 9 month · filed 2018-03-15 | $229.59M derived: sum of 2 quarters · filed 2018-03-15 | $352.76M derived: sum of 3 quarters · filed 2018-03-15 | $470.14M 10-K/A · filed 2018-03-15 | ||||
| 2016-02-28 | $117.06M 10-Q · filed 2017-04-07 | $240.24M derived: sum of 2 quarters · filed 2017-04-07 | $357.61M 10-Q · filed 2017-04-07 | $473.39M derived: sum of 4 quarters · filed 2018-03-15 | ||||
| 2015-11-29 | $123.18M 10-Q · filed 2017-01-05 | $240.55M 10-Q · filed 2017-01-05 | $356.33M derived: sum of 3 quarters · filed 2018-03-15 | $477.98M derived: sum of 4 quarters · filed 2018-03-15 | ||||
| 2015-08-30 | $117.38M 10-Q · filed 2016-09-29 | $233.16M derived: sum of 2 quarters · filed 2018-03-15 | $354.80M derived: sum of 3 quarters · filed 2018-03-15 | $471.80M derived: sum of 4 quarters · filed 2018-03-15 | ||||
| 2015-05-31 | $115.78M derived: 10-K/A 12 month − 10-Q 9 month · filed 2018-03-15 | $237.42M derived: sum of 2 quarters · filed 2018-03-15 | $354.42M derived: sum of 3 quarters · filed 2018-03-15 | $473.85M 10-K/A · filed 2018-03-15 | ||||
| 2015-03-01 | $121.64M 10-Q · filed 2016-03-30 | $238.64M derived: sum of 2 quarters · filed 2016-03-30 | $358.07M 10-Q · filed 2016-03-30 | $462.86M derived: sum of 4 quarters · filed 2016-08-01 | ||||
| 2014-11-30 | $117.00M 10-Q · filed 2016-01-07 | $236.43M 10-Q · filed 2016-01-07 | $341.21M derived: sum of 3 quarters · filed 2016-08-01 | $447.44M derived: sum of 4 quarters · filed 2016-08-01 | ||||
| 2014-08-31 | $119.43M 10-Q · filed 2015-10-01 | $224.21M derived: sum of 2 quarters · filed 2016-08-01 | $330.44M derived: sum of 3 quarters · filed 2016-08-01 | $436.73M derived: sum of 4 quarters · filed 2016-08-01 | ||||
| 2014-05-25 | $104.79M derived: 10-K 12 month − 10-Q 9 month · filed 2016-08-01 | $211.01M derived: sum of 2 quarters · filed 2016-08-01 | $317.30M derived: sum of 3 quarters · filed 2016-08-01 | $414.25M 10-K · filed 2016-08-01 | ||||
| 2014-02-23 | $106.22M 10-Q · filed 2015-04-02 | $105.96M 10-Q · filed 2014-03-28 | $212.52M derived: sum of 2 quarters · filed 2015-04-02 | $309.46M 10-Q · filed 2015-04-02 | $308.28M 10-Q · filed 2014-03-28 | $404.95M derived: sum of 4 quarters · filed 2015-07-31 | ||
| 2013-11-24 | $106.29M 10-Q · filed 2015-01-09 | $105.89M 10-Q · filed 2014-01-03 | $203.24M 10-Q · filed 2015-01-09 | $202.32M 10-Q · filed 2014-01-03 | $298.73M derived: sum of 3 quarters · filed 2015-07-31 | $398.82M derived: sum of 4 quarters · filed 2015-07-31 | ||
| 2013-08-25 | $96.95M 10-Q · filed 2014-10-08 | $96.43M 10-Q · filed 2013-09-26 | $192.43M derived: sum of 2 quarters · filed 2015-07-31 | $292.52M derived: sum of 3 quarters · filed 2015-07-31 | $388.23M derived: sum of 4 quarters · filed 2015-07-31 | |||
| 2013-05-26 | $95.49M derived: 10-K 12 month − 10-Q 9 month · filed 2015-07-31 | $195.58M derived: sum of 2 quarters · filed 2015-07-31 | $291.28M derived: sum of 3 quarters · filed 2015-07-31 | $378.95M 10-K · filed 2015-07-31 | $377.08M 10-K · filed 2013-08-07 | |||
| 2013-02-24 | $100.09M 10-Q · filed 2014-03-28 | $195.80M derived: sum of 2 quarters · filed 2014-03-28 | $283.46M 10-Q · filed 2014-03-28 | $353.28M derived: sum of 4 quarters · filed 2014-08-01 | ||||
| 2012-11-25 | $95.71M 10-Q · filed 2014-01-03 | $183.37M 10-Q · filed 2014-01-03 | $253.19M derived: sum of 3 quarters · filed 2014-08-01 | $319.62M derived: sum of 4 quarters · filed 2014-08-01 | ||||
| 2012-08-26 | $87.66M 10-Q · filed 2013-09-26 | $157.48M derived: sum of 2 quarters · filed 2014-08-01 | $223.91M derived: sum of 3 quarters · filed 2014-08-01 | $291.81M derived: sum of 4 quarters · filed 2014-08-01 | ||||
| 2012-05-27 | $69.82M derived: 10-K 12 month − 10-Q 9 month · filed 2014-08-01 | $136.25M derived: sum of 2 quarters · filed 2014-08-01 | $204.14M derived: sum of 3 quarters · filed 2014-08-01 | $265.41M 10-K · filed 2014-08-01 | $257.21M 10-K · filed 2012-08-08 | |||
| 2012-02-26 | $66.43M 10-Q · filed 2013-04-04 | $65.49M 10-Q · filed 2012-03-28 | $134.33M derived: sum of 2 quarters · filed 2013-04-04 | $195.60M 10-Q · filed 2013-04-04 | $191.78M 10-Q · filed 2012-03-28 | $255.24M derived: sum of 4 quarters · filed 2013-08-07 | ||
| 2011-11-27 | $67.89M 10-Q · filed 2013-01-04 | $66.29M 10-Q · filed 2012-01-05 | $129.16M 10-Q · filed 2013-01-04 | $188.81M derived: sum of 3 quarters · filed 2013-08-07 | $249.13M derived: sum of 4 quarters · filed 2013-08-07 | |||
| 2011-08-28 | $61.27M 10-Q/A · filed 2013-01-02 | $60.00M 10-Q · filed 2011-10-05 | $120.91M derived: sum of 2 quarters · filed 2013-08-07 | $181.23M derived: sum of 3 quarters · filed 2013-08-07 | $237.71M derived: sum of 4 quarters · filed 2013-08-07 | |||
| 2011-05-29 | $59.64M derived: 10-K 12 month − 10-Q 9 month · filed 2013-08-07 | $119.96M derived: sum of 2 quarters · filed 2013-08-07 | $176.44M derived: sum of 3 quarters · filed 2013-08-07 | $227.17M 10-K · filed 2013-08-07 | $223.61M 10-K · filed 2012-08-08 | |||
| 2011-02-27 | $60.32M 10-Q · filed 2012-03-28 | $116.80M derived: sum of 2 quarters · filed 2012-03-28 | $167.52M 10-Q · filed 2012-03-28 | |||||
| 2010-11-28 | $56.48M 10-Q · filed 2012-01-05 | $107.20M 10-Q · filed 2012-01-05 | ||||||
| 2010-08-29 | $50.72M 10-Q · filed 2011-10-05 | |||||||
| 2010-05-30 | $198.07M 10-K · filed 2012-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B |